iniparib
Phase 2- Indications
- Malignant glioma, Glioblastoma
Company intelligence / Profile preview
TriAct Therapeutics
San Francisco, California, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
TriAct Therapeutics is developing iniparib for malignant glioma, which received FDA orphan drug designation in 2021. The company is also developing masoprocol (TT-100), a small molecule inhibitor of tyrosine kinase.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of California at San Francisco
Beyond the preview
Go deeper on TriAct Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TriAct Therapeutics.